Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes
The Journal of Clinical Endocrinology & Metabolism · 07.08.2025 · 110 (9) · e2852-e2863
DOI: 10.1210/clinem/dgaf301 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 27.05.2025. Verfasst von Gwendolyne A Jack und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine-New York Presbyterian, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Healthcare Disparities, Cardiovascular Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Weill Cornell Medicine.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Despite mounting evidence supporting the cardio-kidney benefits of sodium/glucose cotransporter 2 inhibitors (SGLT2i), significant disparities in their use exist among people with type 2 diabetes (T2D), cardiovascular, or kidney disease that reveals a significant disconnect between guidelines and practice. These discrepancies are particularly pronounced among women, minority races, and lower socioeconomic groups. These groups remain underrepresented in major cardiovascular trials, potentially leading to their exclusion from optimal therapies and increasing morbidity and mortality rates. This review aims to highlight disparities in the use of SGLT2i in populations with T2D, chronic kidney disease, heart failure, and atherosclerotic cardiovascular disease. It examines the factors that influence the prescription of SGLT2i within these populations and evaluates their downstream impact on clinical outcomes. Finally, the review summarizes recent clinical trial findings on strategies that enhance the adoption of SGLT2i and other cardioprotective agents through a multifaceted approach, aiming to improve real-world adoption for patients with T2D and/or cardiovascular and kidney diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine-New York Presbyterian, New York, NY 10065, USA.
- Division of Cardiology, Weill Cornell and Houston Methodist Academic Institute, Houston Methodist Hospital, Houston, TX 77030, USA.
- Division of Endocrinology, Diabetes and Metabolism, Weill Cornell and Houston Methodist Academic Institute, Houston, TX 77030, USA.
ORCID-Profile: Archana R Sadhu
Förderung
- Weill Cornell Medicine
Zitieren
APA
Jack, G. A., Avenatti, E., Kashyap, S. R., & Sadhu, A. R. (2025). Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 110(9), e2852-e2863. https://doi.org/10.1210/clinem/dgaf301
Vancouver
Jack GA, Avenatti E, Kashyap SR, Sadhu AR. Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2025;110(9):e2852-e2863. doi:10.1210/clinem/dgaf301
BibTeX
@article{Jack2025,
author = {Jack, Gwendolyne A and Avenatti, Eleonora and Kashyap, Sangeeta R and Sadhu, Archana R},
title = {Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {9},
pages = {e2852--e2863},
doi = {10.1210/clinem/dgaf301}
}
EUVIMED